MA56467A - Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal - Google Patents
Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatalInfo
- Publication number
- MA56467A MA56467A MA056467A MA56467A MA56467A MA 56467 A MA56467 A MA 56467A MA 056467 A MA056467 A MA 056467A MA 56467 A MA56467 A MA 56467A MA 56467 A MA56467 A MA 56467A
- Authority
- MA
- Morocco
- Prior art keywords
- neonatal
- receptor
- directed against
- antibodies directed
- reduced affinity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019902343A AU2019902343A0 (en) | 2019-07-02 | Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56467A true MA56467A (fr) | 2022-05-11 |
Family
ID=74100150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056467A MA56467A (fr) | 2019-07-02 | 2020-07-02 | Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220331457A1 (fr) |
EP (1) | EP3994176A4 (fr) |
JP (1) | JP2022540384A (fr) |
KR (1) | KR20220057516A (fr) |
CN (1) | CN114502596A (fr) |
AU (1) | AU2020299024A1 (fr) |
BR (1) | BR112021026651A2 (fr) |
CA (1) | CA3141457A1 (fr) |
CL (1) | CL2021003561A1 (fr) |
IL (1) | IL289524A (fr) |
MA (1) | MA56467A (fr) |
MX (1) | MX2021015670A (fr) |
WO (1) | WO2021000017A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023028654A1 (fr) * | 2021-09-01 | 2023-03-09 | Telix International Pty Ltd | Procédé de séparation d'agrégats |
WO2023235933A1 (fr) * | 2022-06-09 | 2023-12-14 | Telix Pharmaceuticals (Innovations) Pty Ltd | Polythérapie |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2266448T3 (es) * | 2001-02-07 | 2007-03-01 | Wilex Ag | Linea de celulas de hibridona g250 y su uso para producir anticuerpos monoclonales. |
US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8466263B2 (en) * | 2005-12-02 | 2013-06-18 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase IX (G250) anitbodies |
WO2008091798A2 (fr) * | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Anticorps de ca9 optimises et methodes d'utilisation associees |
CN102775500A (zh) * | 2012-08-03 | 2012-11-14 | 郑骏年 | 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途 |
JP2016528168A (ja) * | 2013-04-29 | 2016-09-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合が無効となった抗IGF−1R抗体及び血管性眼疾患の処置におけるそれらの使用 |
CA2904806C (fr) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Anticorps modifies se liant au fcrn humain et procedes d'utilisation |
MX2016008539A (es) * | 2014-01-15 | 2016-09-26 | Hoffmann La Roche | Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas. |
RU2698969C2 (ru) * | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с улучшенной способностью связываться с белком а |
AU2017223846A1 (en) * | 2016-02-25 | 2018-08-23 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
EP3502139A1 (fr) * | 2017-12-19 | 2019-06-26 | Philogen S.p.A. | Anticorps dirigés contre des antigènes de tumeur |
-
2020
- 2020-07-02 BR BR112021026651A patent/BR112021026651A2/pt unknown
- 2020-07-02 AU AU2020299024A patent/AU2020299024A1/en active Pending
- 2020-07-02 MA MA056467A patent/MA56467A/fr unknown
- 2020-07-02 KR KR1020227002842A patent/KR20220057516A/ko unknown
- 2020-07-02 EP EP20834781.5A patent/EP3994176A4/fr active Pending
- 2020-07-02 WO PCT/AU2020/050689 patent/WO2021000017A1/fr active Application Filing
- 2020-07-02 CN CN202080054196.6A patent/CN114502596A/zh active Pending
- 2020-07-02 JP JP2021578267A patent/JP2022540384A/ja active Pending
- 2020-07-02 MX MX2021015670A patent/MX2021015670A/es unknown
- 2020-07-02 US US17/622,341 patent/US20220331457A1/en active Pending
- 2020-07-02 CA CA3141457A patent/CA3141457A1/fr active Pending
-
2021
- 2021-12-29 CL CL2021003561A patent/CL2021003561A1/es unknown
- 2021-12-30 IL IL289524A patent/IL289524A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220331457A1 (en) | 2022-10-20 |
EP3994176A1 (fr) | 2022-05-11 |
WO2021000017A1 (fr) | 2021-01-07 |
CN114502596A (zh) | 2022-05-13 |
CA3141457A1 (fr) | 2021-01-07 |
KR20220057516A (ko) | 2022-05-09 |
JP2022540384A (ja) | 2022-09-15 |
BR112021026651A2 (pt) | 2022-03-03 |
AU2020299024A1 (en) | 2022-01-20 |
CL2021003561A1 (es) | 2022-11-18 |
MX2021015670A (es) | 2022-04-18 |
EP3994176A4 (fr) | 2023-09-20 |
IL289524A (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA48604A (fr) | Anticorps anti-tim-3 pour une combinaison avec des anticorps anti-pd-1 | |
WO2017123650A3 (fr) | Protéines de fusion se liant à gitr multivalentes et multispécifiques | |
IL276459A (en) | Variable regions of an antibody that targets the NKG2D receptor | |
IL255461A (en) | Antibodies against the transnephrine receptor with adjusted affinity | |
EP3579866A4 (fr) | Domaines variables de chaînes lourdes d'anticorps ciblant le récepteur nkg2d | |
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA46952A (fr) | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet | |
MA43019A (fr) | Anticorps anti-humain cd19 à affinité élevée | |
MA55688A (fr) | Réglage de la temporisation de harq pour pdsch avec indicateur de temporisation pdsch à harq en attente | |
MA56469A (fr) | Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA56467A (fr) | Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal | |
MA55495A (fr) | Protac dégradant le récepteur des éstrogènes | |
MA56466A (fr) | Anticorps anti-epha4 | |
MA52076A (fr) | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 | |
MA55600A (fr) | Anticorps anti-ige | |
MA52075A (fr) | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-l1 | |
DK3963246T3 (da) | Afrivningskobling med vridningssikring | |
EP4029308C0 (fr) | Détermination du type de rat | |
EP3694887A4 (fr) | Anticorps monoclonaux et conjugués dirigés contre l'inhibiteur du récepteur de la prostaglandine f2 et leurs utilisations | |
EP4071167A4 (fr) | Région fc d'anticorps ayant une affinité améliorée à fc?riib | |
EP4073114A4 (fr) | Anticorps anti-albumine sérique | |
MA56394A (fr) | Anticorps anti-angpt2 | |
MA55519A (fr) | Anticorps anti-fgf23 |